Hepatic sEH Drives Osteoclastogenesis via Nrf2 Suppression in Osteoporosis

Study Background and Research Question

Osteoporosis is a prevalent metabolic bone disorder marked by reduced bone mass, impaired microarchitecture, and a heightened risk of fractures, especially in the aging population. Central to its pathogenesis is an imbalance between bone-resorbing osteoclasts and bone-forming osteoblasts. While numerous molecular factors have been implicated in this dysregulation, the role of hepatic lipid metabolism and systemic redox signaling in bone homeostasis remains underexplored.

The reference study (B. Liu et al., 2025) sought to determine whether liver-derived soluble epoxide hydrolase (sEH)—an enzyme involved in the hydrolysis of epoxyeicosatrienoic acids (EETs)—contributes to osteoclast differentiation via modulation of the nuclear factor erythroid 2-related factor 2 (Nrf2) antioxidant signaling pathway. This investigation addresses a critical gap in understanding how systemic lipid metabolism intersects with bone cell function and redox homeostasis.

Key Innovation from the Reference Study

This work presents a novel mechanistic link between hepatic sEH activity and bone metabolism, mediated by the suppression of the Nrf2 signaling pathway. The authors demonstrate that liver-specific sEH acts as a remote regulator of osteoclastogenesis, controlling circulating levels of 14,15-EET and its metabolite 14,15-DHET, and thereby influencing antioxidant responses and inflammatory cytokine production in bone tissue. This "liver-bone axis" provides a new framework for understanding osteoimmunology and systemic regulation of bone remodeling.

Methods and Experimental Design Insights

The study integrated multiple experimental approaches to interrogate the sEH-Nrf2 axis in osteoporosis:

• Clinical sample analysis: Plasma levels of 14,15-EET, 14,15-DHET, and pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) were compared between osteoporosis patients and healthy controls.
• Animal modeling: Ovariectomy (OVX)-induced osteoporosis in mice was used as an established inflammatory pain model for bone loss, enabling assessment of hepatic sEH expression and systemic lipid mediator profiles.
• Pharmacological and genetic interventions: sEH inhibitors and liver-specific sEH knockdown were applied to evaluate their effects on osteoclast differentiation and cytokine milieu.
• Transcriptome sequencing: RNA-seq was employed to dissect the impact of sEH inhibition on gene expression patterns, focusing on the Nrf2-antioxidant response element (ARE) pathway.
• In vitro osteoclastogenesis assays: Direct effects of 14,15-EET on osteoclast differentiation were assessed, including dependence on Nrf2 signaling.

Core Findings and Why They Matter

The main findings of the study are as follows:

• Altered EET/DHET Profile in Osteoporosis: Osteoporosis patients showed decreased plasma 14,15-EET and increased 14,15-DHET, alongside elevated pro-inflammatory cytokines, supporting a shift in epoxyeicosatrienoic acids metabolism toward a pro-inflammatory and pro-resorptive state (reference).
• Hepatic sEH Upregulation Drives Bone Loss: OVX mice exhibited increased hepatic sEH expression, decreased plasma EETs, and enhanced osteoclast differentiation. Importantly, both pharmacological inhibition and liver-specific knockdown of sEH restored EET/DHET balance, reduced inflammation, and ameliorated osteoclastogenesis.
• Nrf2 Pathway as a Downstream Mediator: RNA-seq data revealed that sEH inhibition activates the Nrf2-ARE pathway, which is known to repress oxidative stress and inflammation. Functional assays demonstrated that 14,15-EET directly suppresses osteoclast differentiation in an Nrf2-dependent manner, linking lipid mediator metabolism to redox regulation in bone cells.
• Liver-Bone Axis Conceptualized: The study establishes that hepatic sEH remotely controls bone remodeling by modulating systemic levels of lipid mediators and cytokines, introducing the liver-bone axis as a critical regulator of bone homeostasis under chronic inflammation conditions.

These insights advance our understanding of fatty acid epoxide signaling in osteoporosis and highlight new molecular targets for intervention in chronic inflammation research.

Comparison with Existing Internal Articles

Previous literature, such as "TPPU as a Precision sEH Inhibitor: New Frontiers in Osteoclastogenesis and Lipid Signaling", has emphasized the role of sEH inhibitors like TPPU in modulating osteoclast activity and redox imbalance. These articles underscore the translational potential of targeting sEH in both cell-based and in vivo models, with TPPU emerging as a potent tool for dissecting lipid signaling pathways relevant to bone and inflammatory pain models.

Similarly, "Hepatic sEH Regulates Osteoclastogenesis via Nrf2 in Osteoporosis" reinforces the mechanistic findings of the reference paper, situating sEH at the intersection of lipid metabolism, redox biology, and bone resorption. Collectively, these resources support the robustness of the liver-bone axis model and the use of sEH inhibitors in chronic inflammation research workflows.

Limitations and Transferability

While the study delivers compelling multi-level evidence, several limitations merit consideration:

• Species Differences: Although human plasma samples and mouse models were both assessed, interspecies differences in sEH expression and EET/DHET metabolism may affect the extrapolation of findings.
• Clinical Translation: The current data are preclinical; no clinical trials have yet validated sEH inhibition for osteoporosis or other bone-related disorders.
• Specificity of Modulation: The study focuses on 14,15-EET but does not exclude potential roles for other EET regioisomers or related lipid mediators.
• Complexity of Redox Networks: Nrf2 signaling is highly pleiotropic and context-dependent, suggesting that sEH inhibition may yield tissue-specific or context-specific effects that require further investigation.

Nevertheless, the integrated approach and reproducibility across human and mouse samples enhance the credibility and potential transferability of the findings to broader chronic inflammation research.

Protocol Parameters

• Ovariectomy-induced osteoporosis model: Typically, mice are subjected to bilateral ovariectomy at 8–10 weeks of age, with analysis of bone parameters performed 4–8 weeks post-surgery to model postmenopausal bone loss.
• sEH inhibitor administration: In vivo studies often employ daily oral doses of potent sEH inhibitors, such as TPPU, adjusted to achieve systemic exposure comparable to validated IC₅₀ ranges (2–4 nM for human/mouse sEH, as described in the product information).
• Assessment of EET/DHET and cytokine profiles: Plasma or serum levels are measured using LC-MS/MS and multiplex immunoassays, with sample collection at defined time points post-intervention.
• In vitro osteoclastogenesis: Bone marrow-derived macrophages or monocytes are differentiated with RANKL and M-CSF, with or without sEH inhibitor or EET supplementation.
• Nrf2 pathway analysis: Activation is assessed using ARE-luciferase reporter assays or quantification of Nrf2 target gene expression following treatment.

Research Support Resources

Researchers aiming to investigate sEH-mediated lipid signaling in osteoclastogenesis or related inflammatory pain models can leverage well-characterized tools such as TPPU (SKU C5414), a potent and selective soluble epoxide hydrolase inhibitor validated in both human and mouse systems. TPPU facilitates precise modulation of fatty acid epoxide signaling pathways and has been shown to improve pharmacokinetic parameters and workflow reproducibility in preclinical studies (see guidance). For experimental design and troubleshooting, additional scenario-driven resources are available to support robust and translatable assay outcomes. As always, TPPU is intended for research use only and should be handled according to recommended storage and solubility protocols.